<?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.6.0//EN//XML?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName art560.dtd?>
<?SourceDTD.Version 5.6.0?>
<?ConverterInfo.XSLTName elsevier2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<?origin publisher?>
<?FILEmeta_ISCI104190 xml ?>
<?FILEmain xml ?>
<?FILEmain pdf ?>
<?FILEgr1 jpg ?>
<?FILEgr2 jpg ?>
<?FILEgr3 jpg ?>
<?FILEgr4 jpg ?>
<?FILEgr5 jpg ?>
<?FILEfx1 jpg ?>
<?FILEmmc1 pdf ?>
<?FILEsi1 gif ?>
<?properties open_access?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">iScience</journal-id>
    <journal-id journal-id-type="iso-abbrev">iScience</journal-id>
    <journal-title-group>
      <journal-title>iScience</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2589-0042</issn>
    <publisher>
      <publisher-name>Elsevier</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9035726</article-id>
    <article-id pub-id-type="pii">S2589-0042(22)00460-6</article-id>
    <article-id pub-id-type="doi">10.1016/j.isci.2022.104190</article-id>
    <article-id pub-id-type="publisher-id">104190</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ToPP: Tumor online prognostic analysis platform for prognostic feature selection and clinical patient subgroup selection</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" id="au1">
        <name>
          <surname>Ouyang</surname>
          <given-names>Jian</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="fn1" ref-type="fn">6</xref>
      </contrib>
      <contrib contrib-type="author" id="au2">
        <name>
          <surname>Qin</surname>
          <given-names>Guangrong</given-names>
        </name>
        <xref rid="aff3" ref-type="aff">3</xref>
        <xref rid="fn1" ref-type="fn">6</xref>
      </contrib>
      <contrib contrib-type="author" id="au3">
        <name>
          <surname>Liu</surname>
          <given-names>Zhenhao</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">2</xref>
      </contrib>
      <contrib contrib-type="author" id="au4">
        <name>
          <surname>Jian</surname>
          <given-names>Xingxing</given-names>
        </name>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff4" ref-type="aff">4</xref>
      </contrib>
      <contrib contrib-type="author" id="au5">
        <name>
          <surname>Shi</surname>
          <given-names>Tieliu</given-names>
        </name>
        <email>tieliushi@yahoo.com</email>
        <xref rid="aff1" ref-type="aff">1</xref>
        <xref rid="aff5" ref-type="aff">5</xref>
        <xref rid="cor1" ref-type="corresp">∗</xref>
      </contrib>
      <contrib contrib-type="author" id="au6">
        <name>
          <surname>Xie</surname>
          <given-names>Lu</given-names>
        </name>
        <email>luxiex2017@outlook.com</email>
        <xref rid="aff2" ref-type="aff">2</xref>
        <xref rid="aff4" ref-type="aff">4</xref>
        <xref rid="fn2" ref-type="fn">7</xref>
        <xref rid="cor2" ref-type="corresp">∗∗</xref>
      </contrib>
      <aff id="aff1"><label>1</label>The Center for Bioinformatics and Computational Biology, Shanghai Key Laboratory of Regulatory Biology, the Institute of Biomedical Sciences and School of Life Sciences, East China Normal University, Shanghai 200241, China</aff>
      <aff id="aff2"><label>2</label>Shanghai-MOST Key Laboratory of Health and Disease Genomics, Institute for Genome and Bioinformatics, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200237, China</aff>
      <aff id="aff3"><label>3</label>Institute for Systems Biology, Seattle, WA 98109, USA</aff>
      <aff id="aff4"><label>4</label>Bioinformatics Center, National Clinical Research Centre for Geriatric Disorders, Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, Hunan 410083, China</aff>
      <aff id="aff5"><label>5</label>Big Data and Engineering Research Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China</aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>∗</label>Corresponding author <email>tieliushi@yahoo.com</email></corresp>
      <corresp id="cor2"><label>∗∗</label>Corresponding author <email>luxiex2017@outlook.com</email></corresp>
      <fn id="fn1">
        <label>6</label>
        <p id="ntpara0010">These authors contributed equally</p>
      </fn>
      <fn id="fn2">
        <label>7</label>
        <p id="ntpara0015">Lead contact</p>
      </fn>
    </author-notes>
    <pub-date pub-type="pmc-release">
      <day>04</day>
      <month>4</month>
      <year>2022</year>
    </pub-date>
    <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
    <pub-date pub-type="collection">
      <day>20</day>
      <month>5</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="epub">
      <day>04</day>
      <month>4</month>
      <year>2022</year>
    </pub-date>
    <volume>25</volume>
    <issue>5</issue>
    <elocation-id>104190</elocation-id>
    <history>
      <date date-type="received">
        <day>5</day>
        <month>8</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>19</day>
        <month>1</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>30</day>
        <month>3</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2022 The Author(s)</copyright-statement>
      <copyright-year>2022</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p>
      </license>
    </permissions>
    <abstract id="abs0010">
      <title>Summary</title>
      <p>Patients with cancer with different molecular characterization and subtypes result in different response to anticancer therapeutics and survival. To identify features that are associated with prognosis is essential to precision medicine by providing clues for target identification, drug discovery. Here, we developed a tumor online prognostic analysis platform (ToPP) which integrated eight multi-omics features and clinical data from 68 cancer projects. It provides multiple approaches for customized prognostic studies, including 1) Prognostic analysis based on multi-omics features and clinical characteristics; 2) Automatic construction of prognostic model; 3) Pancancer prognostic analysis in multi-omics data; 4) Explore the impact of different levels of feature combinations on patient prognosis; 5) More sophisticated prognostic analysis according to regulatory network. ToPP provides a comprehensive source and easy-to-use interface for tumor prognosis research, with one-stop service of multi-omics, subtyping, and online prognostic modeling. The web server is freely available at <ext-link ext-link-type="uri" xlink:href="http://www.biostatistics.online/topp/index.php" id="intref0010">http://www.biostatistics.online/topp/index.php</ext-link>.</p>
    </abstract>
    <abstract abstract-type="graphical" id="abs0015">
      <title>Graphical abstract</title>
      <fig id="undfig1" position="anchor">
        <graphic xlink:href="fx1"/>
      </fig>
    </abstract>
    <abstract abstract-type="author-highlights" id="abs0020">
      <title>Highlights</title>
      <p>
        <list list-type="simple" id="ulist0010">
          <list-item id="u0010">
            <label>•</label>
            <p id="p0010">ToPP platform integrated eight multi-omics and clinical data from 68 cancer projects</p>
          </list-item>
          <list-item id="u0015">
            <label>•</label>
            <p id="p0015">ToPP provides multi-omics combination and subgroup selection for prognostic analysis</p>
          </list-item>
          <list-item id="u0020">
            <label>•</label>
            <p id="p0020">ToPP provides automatic construction of prognostic model for public and custom data</p>
          </list-item>
          <list-item id="u0025">
            <label>•</label>
            <p id="p0025">Users can perform prognostic analysis based on regulatory network or pathways in ToPP</p>
          </list-item>
        </list>
      </p>
    </abstract>
    <abstract abstract-type="teaser" id="abs0025">
      <p>Oncology; Public health; Microbiome</p>
    </abstract>
    <kwd-group id="kwrds0010">
      <title>Subject areas</title>
      <kwd>Oncology</kwd>
      <kwd>Public health</kwd>
      <kwd>Microbiome</kwd>
    </kwd-group>
  </article-meta>
  <notes>
    <p id="misc0010">Published: May 20, 2022</p>
  </notes>
</front>
<body>
  <sec id="sec1">
    <title>Introduction</title>
    <p id="p0030">Cancer is among the top fatality diseases which cause approximately 10.0 million deaths worldwide each year (<xref rid="bib34" ref-type="bibr">Sung et al., 2021</xref>). Prognosis analysis is the prediction of the probable outcome from an individual’s current medical condition (<xref rid="bib12" ref-type="bibr">Hansebout et al., 2009</xref>). Many factors are closely related with prognosis in cancer, including age, tumor types, pathological stages, genetic background, and molecular features at different levels (<xref rid="bib3" ref-type="bibr">Banfalvi, 2014</xref>; <xref rid="bib27" ref-type="bibr">Montazeri, 2009</xref>). Prognosis analysis from large patient cohort can help identify biomarkers or potential targets for patients with different clinical outcomes, and it can also evaluate the outcomes of patients with different treatments or in different subgroups. However, it is cumbersome for clinical researchers to conduct prognosis analysis due to lack of follow-up data, clinical data, or statistical skills.</p>
    <p id="p0035">Recently, with the efforts from large consortia, such as The Cancer Genome Atlas (TCGA) (<xref rid="bib40" ref-type="bibr">Weinstein et al., 2013</xref>), International Cancer Genome Consortium (ICGC) (J. <xref rid="bib48" ref-type="bibr">Zhang et al., 2019</xref>), and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) (<xref rid="bib47" ref-type="bibr">Zhang et al., 2016b</xref>), tremendous amount of clinical and omics data have been available to the research community, while the analysis and utilization of these data are still difficult due to the large data size. Several prognosis analysis platforms have been developed. PrognoScan (<xref rid="bib25" ref-type="bibr">Mizuno et al., 2009</xref>) focuses on the microarray datasets of 14 tumors, and provides the minimum log-rank p-value by the best cut-off point. GEPIA (<xref rid="bib35" ref-type="bibr">Tang et al., 2017</xref>) provides not only patient survival analysis but also differential expression analysis, correlation analysis, and dimensionality reduction analysis based on gene expression. Oncolnc (<xref rid="bib1" ref-type="bibr">Anaya, 2016</xref>) contains the relationship between lncRNA, miRNA, mRNA, and prognosis in 21 types of tumors. CaPSSA (<xref rid="bib18" ref-type="bibr">Jang et al., 2019</xref>) provides prognostic analysis at the gene expression and mutation levels. MethSurv (<xref rid="bib26" ref-type="bibr">Modhukur et al., 2018</xref>) is a web server for survival analysis based on methylation data in 25 tumor types in TCGA. However, most of them focused on the prognostic impact of genetic changes at a single level or provide prognosis with fixed subgroups. Practically, it is not robust to evaluate the prognosis of all patients through single prognostic marker due to the complexity of the disease and the heterogeneity of the patients, so it is necessary to establish a more customized, comprehensive, and effective prognostic analysis platform with joint analysis of multi-omics data for user-defined subgroups.</p>
    <p id="p0040">To bridge the gap between the high demand for versatile prognosis analyses from clinical researchers and the big multi-omics datasets, here, we developed the tumor online prognostic analysis platform (ToPP), which provides prognostic analysis using multi-omics (genome, transcriptome, proteome, and epigenome) data and clinical data in both the univariate and multivariate modules. Furthermore, users can build prognostic models or perform pan-cancer prognostic analysis on this platform by submitting their own data. For promoting the application in precision medicine, we also provide in-depth investigation of regulatory relationship or molecular mechanism among prognostic features, as illustrated by four sophisticated case studies on a more precise tumor subgroup stratification.</p>
  </sec>
  <sec id="sec2">
    <title>Result</title>
    <sec id="sec2.1">
      <title>Overview of ToPP</title>
      <p id="p0045">The overview of ToPP is illustrated in <xref rid="fig1" ref-type="fig">Figure 1</xref>. ToPP usage mainly includes four steps: data aggregation, patient stratification, prognosis modeling, and result visualization. ToPP aggregates eight types of multi-omics data and clinical data (<xref rid="tbl1" ref-type="table">Table 1</xref>) from 33 tumors in TCGA (<xref rid="tbl2" ref-type="table">Table 2</xref>), CPTAC and 35 projects in ICGC. It also allows users to upload their in-house data for prognosis analysis. ToPP provides patient stratification through multiple ways. Users can select three conditions when conducting subgroup selection. The phenotype conditions include the patient's clinical data, mainly in physiological and experimental indicators. The molecular conditions are indicators related to molecular characteristics that have been widely used in various tumors, including specific molecular subtypes, immunophenotyping, etc. The genetic conditions are customizable; users can screen specific patient subgroups through a certain molecular feature of interest, thus achieving precise subtyping. Four prognosis modules were provided in ToPP, namely univariate module, multivariate module, pan-cancer module, and combination module, which will be illustrated in the following sections. ToPP also provides a variety of customized charts, such as KM curve, box plot, and calibration curve.<fig id="fig1"><label>Figure 1</label><caption><p>The overview of ToPP workflow</p><p>The data source part shows the datatype collected in ToPP such as genome, transcriptome, proteome, epigenome, and clinical data; the subtype part shows the way for subgroup selection; the analyses part shows the function module in ToPP; and the output part shows the schematic diagram for the results.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Data sources collected in ToPP</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>data type</th><th>Source</th><th>URL</th></tr></thead><tbody><tr><td rowspan="5">Genome</td><td rowspan="2">Mutaion</td><td>UCSC Xena</td><td><ext-link ext-link-type="uri" xlink:href="http://xena.ucsc.edu/" id="intref0130">http://xena.ucsc.edu/</ext-link></td></tr><tr><td>ICGC data portal</td><td><ext-link ext-link-type="uri" xlink:href="https://icgcportal.genomics.cn/" id="intref0135">https://icgcportal.genomics.cn/</ext-link></td></tr><tr><td rowspan="2">CNV</td><td>cBioPortal</td><td><ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/" id="intref0140">https://www.cbioportal.org/</ext-link></td></tr><tr><td>ICGC data portal</td><td><ext-link ext-link-type="uri" xlink:href="https://icgcportal.genomics.cn/" id="intref0145">https://icgcportal.genomics.cn/</ext-link></td></tr><tr><td>Fusion</td><td>TumorFusions</td><td><ext-link ext-link-type="uri" xlink:href="http://www.tumorfusions.org" id="intref0150">http://www.tumorfusions.org</ext-link></td></tr><tr><td rowspan="5">Transcriptome</td><td rowspan="2">mRNA</td><td>UCSC Xena</td><td><ext-link ext-link-type="uri" xlink:href="http://xena.ucsc.edu/" id="intref0155">http://xena.ucsc.edu/</ext-link></td></tr><tr><td>ICGC data portal</td><td><ext-link ext-link-type="uri" xlink:href="https://icgcportal.genomics.cn/" id="intref0160">https://icgcportal.genomics.cn/</ext-link></td></tr><tr><td rowspan="2">miRNA</td><td>UCSC Xena</td><td><ext-link ext-link-type="uri" xlink:href="http://xena.ucsc.edu/" id="intref0165">http://xena.ucsc.edu/</ext-link></td></tr><tr><td>ICGC data portal</td><td><ext-link ext-link-type="uri" xlink:href="https://icgcportal.genomics.cn/" id="intref0170">https://icgcportal.genomics.cn/</ext-link></td></tr><tr><td>LncRNA</td><td>TANRIC</td><td><ext-link ext-link-type="uri" xlink:href="https://ibl.mdanderson.org/tanric/_design/basic/index.html" id="intref0175">https://ibl.mdanderson.org/tanric/_design/basic/index.html</ext-link></td></tr><tr><td rowspan="2">Proteome</td><td>RPPA</td><td>UCSC Xena</td><td><ext-link ext-link-type="uri" xlink:href="http://xena.ucsc.edu/" id="intref0180">http://xena.ucsc.edu/</ext-link></td></tr><tr><td>iTRAQ</td><td>CPTAC</td><td><ext-link ext-link-type="uri" xlink:href="https://cptac-data-portal.georgetown.edu/cptacPublic/" id="intref0185">https://cptac-data-portal.georgetown.edu/cptacPublic/</ext-link></td></tr><tr><td rowspan="2">Epigenome</td><td rowspan="2">Methylation</td><td>UCSC Xena</td><td><ext-link ext-link-type="uri" xlink:href="http://xena.ucsc.edu/" id="intref0190">http://xena.ucsc.edu/</ext-link></td></tr><tr><td>ICGC data portal</td><td><ext-link ext-link-type="uri" xlink:href="https://icgcportal.genomics.cn/" id="intref0195">https://icgcportal.genomics.cn/</ext-link></td></tr><tr><td rowspan="3">Clinical data</td><td rowspan="3">Phenotype &amp;Follow up</td><td>UCSC Xena</td><td><ext-link ext-link-type="uri" xlink:href="http://xena.ucsc.edu/" id="intref0200">http://xena.ucsc.edu/</ext-link></td></tr><tr><td>cBioPortal</td><td><ext-link ext-link-type="uri" xlink:href="https://www.cbioportal.org/" id="intref0205">https://www.cbioportal.org/</ext-link></td></tr><tr><td>ICGC data portal</td><td><ext-link ext-link-type="uri" xlink:href="https://icgcportal.genomics.cn/" id="intref0210">https://icgcportal.genomics.cn/</ext-link></td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Multi-omics data of 33 types of cancer from TCGA included in ToPP</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Type</th><th colspan="2">Genome<hr/></th><th colspan="4">Transcriptome<hr/></th><th colspan="2">Proteome<hr/></th><th>Epigenome<hr/></th><th>Clinical data<hr/></th></tr><tr><th>Mutation</th><th>CNV</th><th>Fusion</th><th>mRNA</th><th>miRNA</th><th>LncRNA</th><th>RPPA</th><th>MS</th><th>Methylation</th><th>Phenotype</th></tr></thead><tbody><tr><td>TCGA-ACC</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-BLCA</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-BRCA</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td></tr><tr><td>TCGA-CESC</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-CHOL</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-COAD</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td></tr><tr><td>TCGA-DLBC</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-ESCA</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-GBM</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-HNSC</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-KICH</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-KIRC</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-KIRP</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-LAML</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>NA</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-LGG</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-LIHC</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-LUAD</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-LUSC</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-MESO</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-OV</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td></tr><tr><td>TCGA-PAAD</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-PCPG</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-PRAD</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-READ</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td></tr><tr><td>TCGA-SARC</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-SKCM</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-STAD</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-TGCT</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-THCA</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-THYM</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-UCEC</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-UCS</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr><tr><td>TCGA-UVM</td><td>√</td><td>√</td><td>√</td><td>√</td><td>√</td><td>NA</td><td>√</td><td>NA</td><td>√</td><td>√</td></tr></tbody></table><table-wrap-foot><fn><p>∗ RPPA: Reverse phase protein array; √: with data; NA: without data.</p></fn></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="sec2.2">
      <title>Prognosis modules</title>
      <p id="p0050">The univariate module focuses on the impact of a single variable (genetic or clinical) on prognosis. Genetic features contain gene or protein expression changes, DNA variation, and epigenome changes. Users can select the datasets, data types, and variables to their interest. If the variable is continuous, the default patient stratification strategy is to use the median value for this variable (eg. Gene expression value) across all samples selected as a cutoff. In clinical research, especially in the demand of precision medicine, researchers may focus on the performance of prognostic factors in a particular subgroup, we therefore developed conditional screening tool to meet the subgroup screening. The conditional screening is based on gene mutation, methylation changes, or clinical classification. The univariate module provides a KM curve, the log-rank p-value, and hazard ratio of the two groups of patients. Meanwhile, users can make adjustments to the KM curve visualization, such as risk table, group color, unit time, median survival, and hazard ratio (HR). Furthermore, boxplot for the gene expression in tumor and normal groups can be drawn if the user sets the radio named differential expression to “yes”.</p>
      <p id="p0055">Multivariate module provides prognosis analysis for multiple variables, such as for a given gene list. The result for multivariate module contains a table with five columns: gene list, univariate analysis log-rank p-value and hazard ratio, and multivariate analysis log-rank p-value and hazard ratio for each gene, so that users can screen out the independent prognostic factors. In addition, it also provides the function of prognostic modeling, which includes model building, model evaluation, model diagnosis, and model validation. With the input of a gene list, the selection of training set and verification set, ToPP will automatically build the model by default parameters which are set by common processes. After checking the performance of the model in the training set and validation set (such as the three- or five-year calibration curve, C-index and 1000 bootstrap validator) and the results of the model diagnosis (PH assumption, outliers, and nonlinearity), users can adjust the model accordingly by further variable selection, nonlinear transformation. Users can also consider the interaction of covariates or time-dependent covariates.</p>
      <p id="p0060">Pan-cancer module was designed to investigate the prognostic effects of factors in a variety of tumors. All data were acquired from the Pan-Cancer Atlas (<xref rid="bib17" ref-type="bibr">Hoadley et al., 2018</xref>) with unified normalization and standardization. Users can select all types of cancer or just choose a subset (<xref rid="mmc1" ref-type="supplementary-material">Table S2</xref>) of pan-cancers such as urologic (bladder urothelial carcinoma [BLCA], prostate adenocarcinoma [PRAD], testicular germ cell tumors [TGCT], kidney renal clear cell carcinoma [KIRC], kidney chromophobe [KICH], and kidney renal papillary cell carcinoma [KIRP]) which was designed by Pan-Cancer Atlas project. The following up patient stratification and prognosis modeling approach are as the same as the univariate module. Besides, ToPP also includes the high frequently mutated gene lists in the ten canonical pathways which are, cell cycle, Hippo, Myc, Notch, Nrf2, PI-3-Kinase/Akt, RTK-RAS, TGFβ signaling, p53, and beta-catenin/Wnt (<xref rid="bib32" ref-type="bibr">Sanchez-Vega et al., 2018</xref>), and it can facilitate users to explore how the alterations (copy-number alterations, mutations, fusions, or epigenetic silencing) of genes in these pathways impact prognosis in different tumor types. The results will show the log-rank p, HR, and KM curve for each type of cancer as well as the pan-cancer.</p>
      <p id="p0065">Combination module allows users to input multiple levels of data for two genes separately. It allows for more precise stratification of patients. For example, given a condition of mutation of one gene, researchers may want to know whether the mutation or expression of its regulated gene will have an impact on the patient's survival. Through the combination module, the samples would be subdivided into four subgroups; each subgroup has more clear molecular characteristics. By analyzing whether there are significant differences in survival among the four subgroups, users can carry out molecular subtyping of patients.</p>
      <sec id="sec2.2.5">
        <title>Data upload module</title>
        <p id="p0070">Data upload module allows users to upload their own data with survival time and status to conduct all kinds of analysis in ToPP. Also, users are advised to set the permission limit for their own data and use an e-mail for contact if necessary.</p>
      </sec>
    </sec>
    <sec id="sec2.3">
      <title>Case studies in ToPP</title>
      <sec id="sec2.3.1">
        <title>Lipid metabolism affects cancer survival</title>
        <p id="p0075">Our previous study has shown lipid metabolism in cancer shows significant prognosis effects (<xref rid="bib13" ref-type="bibr">Hao et al., 2019</xref>). PPAR signaling pathway is a key signaling pathway that regulates lipid metabolism. Both peroxisome proliferator-activated receptor (PPAR) α and PPARγ were reported to regulate the expression of 3-hydroxy-3-methylglutaryl CoA synthase 2 (HMGCS2) (<xref rid="bib19" ref-type="bibr">Kim et al., 2019</xref>; VilÃ -<xref rid="bib37" ref-type="bibr">Brau et al., 2011</xref>). To comprehensively investigate the impact of PPAR signaling pathway and HMGCS2 on patient outcomes, we performed analyses using multiple modules in ToPP. The univariate analysis result show that patients with kidney renal clear cell carcinoma (KIRC) with lower expression of HMGCS2 are associated with worse prognosis (<xref rid="fig2" ref-type="fig">Figure 2</xref>A) and it shows downregulation in tumor samples compared with normal samples (<xref rid="fig2" ref-type="fig">Figure 2</xref>B). In order to study the influence of the gene sets on the prognosis, the gene list in PPAR signaling pathway which related to tumor prognostics as we previous reported (<xref rid="bib13" ref-type="bibr">Hao et al., 2019</xref>) were inputted for multivariate analysis in KIRC dataset, and our results show the different status of PPAR signaling pathway can distinguish the prognosis of patients with KIRC (<xref rid="fig2" ref-type="fig">Figure 2</xref>C). To address the combinatory prognostic effects for HMGCS2 and other driver genes, we also make a combinatory prognostic analysis using the combinatory module. Von Hippel-Lindau (VHL) is the most frequently mutated gene in patients with KIRC; we then performed the combination analysis for the VHL and HMGCS2. Interestingly, patients who have lower expression of HMGCS2 and with no mutation in VHL show poorer prognosis than other subgroups (<xref rid="fig2" ref-type="fig">Figure 2</xref>D). In order to explain this result, we propose two potential hypotheses through literature research. First one is that VHL directly interacted with and promoted ubiquitination of PPARγ leading to its degradation, and inhibition of PPARγ reduced HMGCS2 expression (<xref rid="bib15" ref-type="bibr">Hernandez-Quiles et al., 2021</xref>; <xref rid="bib19" ref-type="bibr">Kim et al., 2019</xref>; <xref rid="bib28" ref-type="bibr">Noh et al., 2020</xref>). The other is that VHL is suggested as mutated as an early event for tumor, and HMGCS2 may have a negative regulation of tumor angiogenesis (<xref rid="bib10" ref-type="bibr">Gossage et al., 2015</xref>; <xref rid="bib49" ref-type="bibr">Zou et al., 2019</xref>). And their impact on prognosis may be independent. For more evidence to confirm these hypotheses, researchers need to do more experiments to verify them. To further investigate whether HMGCS2 is associated with prognosis in different tumor types, we perfomed the pan-cancer analysis for HMGCS2 in ToPP using the pan-cancer analysis module. The results show that HMGCS2 has the similar pattern in a variety of tumors (<xref rid="fig2" ref-type="fig">Figures 2</xref>E and 2F), including liver hepatocellular carcinoma (LIHC), bladder urothelial carcinoma (BLCA), brain lower-grade glioma (LGG), and KIRC.<fig id="fig2"><label>Figure 2</label><caption><p>Research on lipid-metabolism-related genes in ToPP</p><p>(A) The univariate analysis module results show that patients with kidney renal clear cell carcinoma (KIRC) with lower expression of HMGCS2 have poor prognostic (log-rank test, p = 0.00041).</p><p>(B) KIRC samples have lower expression compared with normal samples (p &lt; 0.0001, wilcoxon rank sum test).</p><p>(C) Multivariate analysis module results show that the genes which are significantly associated with prognosis of patients with tumor in PPAR pathway (CPT2, ACADL, FADS2, CPT1B, CPT1C, ACOX3, CYP27A1, LDLR, ANGPTL4, CD36, SLC27A2, ACOX2, FABP6, HMGCS2, PLIN4, PLIN5, PPARG, MMP1, PCK1, PLIN2, GK, NR1H3, PPARD, OLR1, RXRB, PDPK1, and RXRA) have a significant impact on the prognosis of patients with KIRC (log-rank test, p &lt; 0.0001).</p><p>(D) The Combination module reveals that the KIRC subgroup of patients with low expression of HMGCS2 and no somatic mutation in VHL may have the highest risk (log-rank test, p = 0.0016).</p><p>(E and F) HMGCS2 has the similar pattern in a variety of tumors including liver hepatocellular carcinoma (LIHC), bladder urothelial carcinoma (BLCA), brain lower-grade glioma (LGG), and KIRC (log-rank test, p &lt; 0.0001).</p></caption><graphic xlink:href="gr2"/></fig></p>
      </sec>
      <sec id="sec2.3.2">
        <title>Regulatory relationship investigation through multi-omics prognostic analysis in ToPP</title>
        <p id="p0080">Poly (ADP-ribose) polymerase 3 (PARP3) is the third member of the PARP family and it can accelerate the repair of chromosomal DNA single-strand breaks (<xref rid="bib11" ref-type="bibr">Grundy et al., 2016</xref>). Researches reported that PARP3 is a driver gene to TGFβ-induced epithelial-to-mesenchymal transition and its inhibitors sensitize breast cancer cells to vinorelbine which was used in the treatment of metastatic breast cancer (<xref rid="bib4" ref-type="bibr">Beck et al., 2019</xref>; <xref rid="bib33" ref-type="bibr">Sharif-Askari et al., 2018</xref>). Here, we investigate the prognosis effect of PARP3 in patients with breast cancer. Firstly, we explored the relationship between PARP3 expression and overall survival in ToPP, and the result showed that patients with higher expression of PARP3 had a better prognosis than the patients with lower expression of PARP3 in TCGA-BRCA cohort (p = 0.0035, <xref rid="fig3" ref-type="fig">Figure 3</xref>A). This conclusion could be verified in other two independent datasets BRCA-FR and BRCA-KR in ICGC Data Portal (p = 0.046, <xref rid="fig3" ref-type="fig">Figure 3</xref>B, p = 0.045, <xref rid="fig3" ref-type="fig">Figure 3</xref>C). Then, we further investigated the prognosis effect of PARP3 in patients with breast cancer with both proteomic and genomic data, and the results were consistent, which mean that PARP3 is still a protection factor to patients in proteomic level (p = 0.047, <xref rid="fig3" ref-type="fig">Figure 3</xref>D). Meanwhile, patients with PARP3 mutation have a poor prognosis (p = 0.00098, <xref rid="fig3" ref-type="fig">Figure 3</xref>E). To look for regulatory factors to the gene that we are interested in, and use the regulatory relationship to provide more evidence for the predicted survival effects, we searched for related miRNAs in the miRDB (<xref rid="bib6" ref-type="bibr">Chen and Wang, 2020</xref>) database with PARP3 as the target gene, and performed the prognostic analysis for all these miRNAs in ToPP. Interestingly, one of the PARP3-related miRNA hsa-miR-98-3p showed that patients with higher expression of hsa-miR-98-3p indicated a poorer prognosis (p = 0.012, <xref rid="fig3" ref-type="fig">Figure 3</xref>F). As miRNAs mediated silencing and repression of their targeted mRNA molecules, the observations of both the higher expression of has-miR-98-3p and the lower expression of its target gene PARP3 associated with a poorer prognosis provide us higher confidence of the effects of the has-miR-98-3p-PARP3 regulatory relationship to survival. In addition, we found that the expression of hsa-miR-98-3p in tumor tissues was significantly higher than that in adjacent tissues (wilcoxon rank sum test, p &lt; 0.001, <xref rid="fig3" ref-type="fig">Figure 3</xref>G) in patients with BRCA, but PARP3 showed the opposite expression pattern (wilcoxon rank sum test, p &lt; 0.001, <xref rid="fig3" ref-type="fig">Figure 3</xref>H). Correlation analysis of hsa-miR-98-3p and PARP3 expression in tumor tissues of patients with BRCA also suggested the significant correlation between the expression levels of hsa-miR-98-3p and PARP3 (spearman correlation, p &lt; 2.2e-16, R = −0.36 <xref rid="fig3" ref-type="fig">Figure 3</xref>I). Previous studies have found that hsa-miR-98-5p overexpression could increase breast cancer cells proliferation, migration, and invasion indicating that hsa-miR-98-5p functions as an oncogenic role in breast cancer (<xref rid="bib38" ref-type="bibr">Wang et al., 2018</xref>). However, the role of hsa-miR-98-3p in breast cancer was not clear. Through our case study result here, we might speculate that hsa-miR-98-3p could have affected the repair of chromosomal DNA single-strand breaks by negatively regulating PARP3, thereby affecting the prognosis of patients with BRCA. Or such analysis result could justify more functional experimental validation. This case study also demonstrates that ToPP can provide multiple-omic molecular feature selection in prognostic research.<fig id="fig3"><label>Figure 3</label><caption><p>Multi-omics prognostic analysis in ToPP</p><p>(A) Prognosis analysis of PARP3 mRNA expression in TCGA-BRCA cohort, patients with higher expression of PARP3 have better prognosis (log-rank test, p &lt; 0.0035, HR: 0.621 95%CI: 0.45–0.858). So it is in two independent datasets (B and C).</p><p>(D) The prognosis analysis of expression of PARP3 in protein level (iTRAQ) also indicates PARP3 is a protection factor to patients with breast cancer (log-rank test, p = 0.047).</p><p>(E) Patients with PARP3 mutation may have poor prognosis (log-rank test, p = 0.00098).</p><p>(F) High expression of hsa-miR-98-3p was significantly associated with poor prognosis in patients with breast cancer (log-rank test, p = 0.012).</p><p>(G) The expression for hsa-miR-98-3p in BRCA tumor tissue and adjacent normal tissue (wilcoxon rank sum test, ∗∗∗, p &lt; 0.001).</p><p>(H) The expression for PARP3 in BRCA tumor tissue and adjacent normal tissue (wilcoxon rank sum test, ∗∗∗, p &lt; 0.001).</p><p>(I) Correlation between the expression of hsa-miR-98-3p and PARP3 in tumor tissue (spearman correlation, p &lt; 2.2e-16, R = −0.36).</p></caption><graphic xlink:href="gr3"/></fig></p>
      </sec>
      <sec id="sec2.3.3">
        <title>Automatic gene set feature optimization and validation of a prognostic model for a certain cancer type in ToPP</title>
        <p id="p0085">Owing to the complexity and heterogeneity of diseases, it remains a challenge to accurately predict the prognosis of all patients using a single marker. Therefore, it is desirable to combine different signatures to construct a versatile prognostic model to predict outcome. However, building a stable prognostic model requires sophisticated statistical skills and profound medical knowledge which may be cumbersome for researchers. Here, we illustrate a case study to build a prognostic model automatically with a set of gene signatures to predict prognosis for one cancer type using ToPP. Let’s take liver cancer as an example. ToPP provides two independent liver cancer cohorts with gene expression data and complete clinical follow-up data (OS), one cohort with 365 samples obtained from TCGA, and the other cohort with 232 samples from the LIRI-JP project downloaded from ICGC Data Portal (<xref rid="bib9" ref-type="bibr">Fujimoto et al., 2016</xref>). We used the normalized read count values available in the gene expression file. We set the TCGA-LIHC cohort as the training set and LIRI-JP cohort as the validation set. Firstly, we selected univariate analysis function in ToPP to screen out the top 10 genes (KPNA2, G6PD, SFPQ, SOCS2, EZH2, RAMP3, UCK2, GTPBP4, CBX2, and LIMS2) which are most relevant to the prognosis (OS) of liver cancer in gene expression level (<xref rid="mmc1" ref-type="supplementary-material">Table S3</xref>). Then, the expressions of these genes were used as candidate features for model construction. We chose AIC as model selection in a stepwise (select backward) algorithm. Eventually, a four-gene (karyopherin subunit alpha 2(KPNA2), suppressor of cytokine signaling 2(SOCS2), GTP-binding protein 4(GTPBP4), and chromobox 2(CBX2)) signature model was constructed by multivariate analysis showing that they were independent prognostic factors for liver cancer (<xref rid="tbl3" ref-type="table">Table 3</xref>).<table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Univariate and multivariate analysis for a four-gene signature for the prognosis of liver cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">symbol</th><th colspan="2">Univariate<hr/></th><th colspan="2">Multivariate<hr/></th></tr><tr><th>HR(%95CI)</th><th>p value</th><th>HR(%95CI)</th><th>p value</th></tr></thead><tbody><tr><td>CBX2</td><td>1.90:(1.33–2.69)</td><td>2.90E-04</td><td>1.15:(1.02–1.30)</td><td>2.48E-02</td></tr><tr><td>GTPBP4</td><td>2.38:(1.663.41)</td><td>1.29E-06</td><td>1.49:(1.06–2.09)</td><td>2.20E-02</td></tr><tr><td>KPNA2</td><td>2.28:(1.60–3.27)</td><td>3.43E-06</td><td>1.31:(1.04–1.66)</td><td>2.18E-02</td></tr><tr><td>SOCS2</td><td>0.457:(0.319–0.654)</td><td>1.13E-05</td><td>0.82:(0.72–0.93)</td><td>1.46E-03</td></tr></tbody></table></table-wrap></p>
        <p id="p0090">To prove the effect of our automatically generated prognosis model, we validated the model by the following analyses. The C-index with 1000 bootstrap replications in the training cohort (TCGA-LIHC) was 0.724 and 0.752 in validation cohort (LIRI-JP). We stratified the samples into two groups (high-risk or low-risk) according to the median value of the <inline-formula><mml:math id="M1" altimg="si1.gif"><mml:mrow><mml:mtext>risk score</mml:mtext><mml:mo linebreak="goodbreak" linebreakstyle="after">=</mml:mo><mml:mn>0.272</mml:mn><mml:mtext>∗KPNA</mml:mtext><mml:mn>2</mml:mn><mml:mo linebreak="goodbreak" linebreakstyle="after">−</mml:mo><mml:mn>0.202</mml:mn><mml:mtext>∗SOCS</mml:mtext><mml:mn>2</mml:mn><mml:mo linebreak="goodbreak" linebreakstyle="after">+</mml:mo><mml:mn>0.396</mml:mn><mml:mtext>∗GTPBP</mml:mtext><mml:mn>4</mml:mn><mml:mo linebreak="goodbreak" linebreakstyle="after">+</mml:mo><mml:mn>0.138</mml:mn><mml:mtext>∗CBX</mml:mtext><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula>. KM curve was drawn with these two groups, and the log-rank test was with p &lt; 0.0001 (<xref rid="fig4" ref-type="fig">Figure 4</xref>A). Besides, Cox model diagnosis and validation was performed simultaneously. The results show that all covariates satisfy the proportional hazards (PH) assumption and the global test of this Cox regression model is 0.212, which means the model as a whole meets the PH assumption (<xref rid="fig4" ref-type="fig">Figure 4</xref>B). A nomogram that incorporated all of the significant independent factors for predicting the 3-year and 5-year survival rates in the testing cohort was established (<xref rid="fig4" ref-type="fig">Figure 4</xref>D) and the associated calibration curves from the nomograms at 3 and 5 years are shown in <xref rid="fig4" ref-type="fig">Figure 4</xref>C.<fig id="fig4"><label>Figure 4</label><caption><p>Four-gene signature-predictive prognosis model in liver cancer</p><p>(A) The risk score calculated with KPNA2, SOCS2, GTPBP4, and CBX2 could assess patient prognosis (log-rank test, p &lt; 0.0001).</p><p>(B) Four covariates fit proportional hazards (PH) assumption for a Cox regression model (Schoenfeld test, p = 0.2116).</p><p>(C) 3-years and 5-years calibration curves showing model-predicted survival vs. observed fraction.</p><p>(D) Nomogram based on four-gene signature predicting patient outcome in 3 and 5 years.</p></caption><graphic xlink:href="gr4"/></fig></p>
      </sec>
      <sec id="sec2.3.4">
        <title>Investigation of mutation-expression regulation by sub-stratification prognosis analysis in ToPP: patients with high expression of HIST2H3C have poor prognosis only in IDH1 mutation subgroup of lower-grade glioma</title>
        <p id="p0095">The featured combination module in ToPP can help us to have better stratification of patients and understand the prognostic effects. As an example, here we used the mutation of isocitrate dehydrogenase 1(IDH1) as a condition for patient stratification and prognosis analysis. IDH1 is one of the most commonly mutated genes in diffuse lower-grade gliomas (LGGs), and it is significantly related to the prognosis of LGG (<xref rid="bib8" ref-type="bibr">Deng et al., 2019</xref>). IDH1/2 mutations are thought to result in hypermethylated histones and DNA (<xref rid="bib30" ref-type="bibr">Raineri and Mellor, 2018</xref>). In order to investigate the effect of IDH1 and histone status on the prognosis of patients with LGG, here, we selected H3 clustered histone 14 (H3C14, also known as HIST2H3C), which plays a central role in transcription regulation, DNA repair, DNA replication, and chromosomal stability as an example (<xref rid="bib16" ref-type="bibr">Herranz et al., 2016</xref>). Firstly, we retrieved the effect of HIST2H3C expression level on prognosis in LGG, and found that there was no significant (p = 0.32, <xref rid="fig5" ref-type="fig">Figure 5</xref>A) difference between high expression and low expression groups in overall survival (OS). In order to examine whether HIST2H3C expression has an effect on prognosis when IDH1 is mutated, we divided the patients into two groups: IDH1 mutation group and IDH1 wild-type group in ToPP. The results showed that patients with higher expression of HIST2H3C have poorer prognosis in overall survival (OS), progression-free interval (PFI), disease-specific survival (DSS), disease-free interval (DFI), and relapse-free survival (RFS) in the IDH1-mutated group (p &lt; 0.0001, HR = 2.69; p = 0.00012, HR = 2.0; p &lt; 0.0001, HR = 3.23; p = 0.017, HR = 3.26; p = 0.016, HR = 1.64, <xref rid="fig5" ref-type="fig">Figures 5</xref>B and <xref rid="mmc1" ref-type="supplementary-material">S1</xref>). However, this phenomenon was not found in IDH1 wild-type group (p = 0.93, <xref rid="fig5" ref-type="fig">Figure 5</xref>C). Further investigation found that the isocitrate dehydrogenase (IDH) mutant is related to increased methylation of histone lysine residues (<xref rid="bib36" ref-type="bibr">Venneti et al., 2013</xref>), while, methylation of some lysine and arginine residues of histones results in transcriptional activation (<xref rid="bib41" ref-type="bibr">Whetstine, 2010</xref>). Moreover, we found that the expression of HIST2H3C in patients with LGG with IDH1 mutation was significantly higher than that in IDH1 wild-type patients (wilcoxon rank sum test, p &lt; 0.001, <xref rid="fig5" ref-type="fig">Figure 5</xref>D). The above evidence shows that HIST2H3C affects the prognosis of patients through a joint effect with IDH1 mutation. In subsequent mechanism or drug research, it may suggest a new approach to treat LGG by inhibiting HIST2H3C expression when the IDH1 gene is mutated.<fig id="fig5"><label>Figure 5</label><caption><p>Patients with lower-grade gliomas (LGG) with high expression of HIST2H3C have poor prognosis only in IDH1 mutation subgroup</p><p>(A) Prognosis analysis of HIST2H3C mRNA expression in 528 patients with LGG shows no significant difference (log-rank test, p = 0.32) for patient outcome.</p><p>(B) High expression of HIST2H3C has poor prognostic (log-rank test, p &lt; 0.0001, HR: 2.69 95%CI: 1.61–4.5) in IDH1 mutation subgroup.</p><p>(C) There is no significant difference (log-rank test, p = 0.93) in IDH1 wild-type subgroup.</p><p>(D) Patients with LGG have higher expression of HIST2H3C in IDH1 mutation subgroup than IDH1 wild-type subgroup (wilcoxon rank-sum rank sum test, ∗∗∗∗, p &lt; 0.0001).</p></caption><graphic xlink:href="gr5"/></fig></p>
      </sec>
    </sec>
  </sec>
  <sec id="sec3">
    <title>Discussion</title>
    <p id="p0100">ToPP is an interactive web application for survival analysis for multi-omics data (genome, transcriptome, proteome, epigenome, and clinical data) of 68 cancer projects from the TCGA, CPTAC, and ICGC Data Portal. It collects comprehensive, standardized data. Therefore, it is at the first place in an affluent data repository for versatile cancer prognostic features. Genes or proteins can be searched in ToPP to check on its prognostic value in multiple published datasets.</p>
    <p id="p0105">ToPP provides flexible and comprehensive prognosis analysis modules, such as univariate, multivariate, combined, patient subgroup stratification survival analysis, self-designed prognostic model construction, and pan-cancer prognosis analysis module. Also, users can upload their own data for prognostic modeling and analysis.</p>
    <p id="p0110">All the data resources and analysis functions are provided in a friendly and simple interface for the convenient application to experimental cancer researchers. For more advanced computational biologists, the scripts in our GitHub account with full resources are also provided.</p>
    <sec id="sec3.1">
      <title>Limitations of the study</title>
      <p id="p0115">There are also some limitations in ToPP. It only contains relatively common types of tumors, which may not be suitable for some specific types of tumors or other types of diseases. The clinical subtype annotation information of some tumors is not comprehensive enough, such as liver cancer or colon adenocarcinoma and so on. The molecular subgroup does not include the mutation sites, alternative splicing, or integrated signatures such as tumor mutation burden, which we notice are being increasingly studied in cancer prognosis. The analytical conclusions obtained by our platform are all data-driven which may lack more biological explanations and experiments to validate the results. We will keep expanding the data repository and function panels of ToPP to make it a sustainable resource for cancer researchers.</p>
    </sec>
  </sec>
  <sec id="sec5">
    <title>STAR★Methods</title>
    <sec id="sec5.1">
      <title>Key resources table</title>
      <p id="p0125">
        <table-wrap position="float" id="undtbl1">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th>REAGENT or RESOURCE</th>
                <th>SOURCE</th>
                <th>IDENTIFIER</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td colspan="3">
                  <bold>Deposited data</bold>
                </td>
              </tr>
              <tr>
                <td colspan="3">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td>Code for analyses</td>
                <td>This paper</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://github.com/kbvstmd/ToPP" id="intref0015">https://github.com/kbvstmd/ToPP</ext-link>
                </td>
              </tr>
              <tr>
                <td>multi-omics data and clinical data</td>
                <td>This paper</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="http://www.biostatistics.online/topp/index.php" id="intref0020">http://www.biostatistics.online/topp/index.php</ext-link>
                </td>
              </tr>
              <tr>
                <td colspan="3">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td colspan="3">
                  <bold>Software and algorithms</bold>
                </td>
              </tr>
              <tr>
                <td colspan="3">
                  <hr/>
                </td>
              </tr>
              <tr>
                <td>R 3.5.0</td>
                <td>R Core Team</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://www.rproject.org/" id="intref0025">https://www.rproject.org/</ext-link>
                </td>
              </tr>
              <tr>
                <td>MySQL 5.7.17</td>
                <td>Oracle Corporation</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://www.mysql.com/" id="intref0030">https://www.mysql.com/</ext-link>
                </td>
              </tr>
              <tr>
                <td>PHP 7.0.12</td>
                <td>The PHP Group</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://www.php.net/" id="intref0035">https://www.php.net/</ext-link>
                </td>
              </tr>
              <tr>
                <td>rms 5.4.1</td>
                <td>(<xref rid="bib29" ref-type="bibr">Núñez et al., 2011</xref>)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/rms/index.html" id="intref0040">https://cran.r-project.org/web/packages/rms/index.html</ext-link>
                </td>
              </tr>
              <tr>
                <td>survminer 0.4.6</td>
                <td>Alboukadel Kassambara (<ext-link ext-link-type="uri" xlink:href="mailto:alboukadel.kassambara@gmail.com" id="intref0045">alboukadel.kassambara@gmail.com</ext-link>)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/survminer/index.html" id="intref0050">https://cran.r-project.org/web/packages/survminer/index.html</ext-link>
                </td>
              </tr>
              <tr>
                <td>stringr 1.4.0</td>
                <td>(<xref rid="bib42" ref-type="bibr">Wickham et al., 2019</xref>)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/stringr/index.html" id="intref0055">https://cran.r-project.org/web/packages/stringr/index.html</ext-link>
                </td>
              </tr>
              <tr>
                <td>data.Table 1.12.8</td>
                <td>Matt Dowle (<ext-link ext-link-type="uri" xlink:href="mailto:mattjdowle@gmail.com" id="intref0060">mattjdowle@gmail.com</ext-link>)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/data.table/index.html" id="intref0065">https://cran.r-project.org/web/packages/data.table/index.html</ext-link>
                </td>
              </tr>
              <tr>
                <td>dplyr 0.8.5</td>
                <td>(<xref rid="bib42" ref-type="bibr">Wickham et al., 2019</xref>)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/dplyr/index.html" id="intref0070">https://cran.r-project.org/web/packages/dplyr/index.html</ext-link>
                </td>
              </tr>
              <tr>
                <td>forestplot 1.9</td>
                <td>Max Gordon (<ext-link ext-link-type="uri" xlink:href="mailto:max@gforge.se" id="intref0075">max@gforge.se</ext-link>)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/forestplot/index.html" id="intref0080">https://cran.r-project.org/web/packages/forestplot/index.html</ext-link>
                </td>
              </tr>
              <tr>
                <td>ggpubr 0.2.5</td>
                <td>Alboukadel Kassambara (<ext-link ext-link-type="uri" xlink:href="mailto:alboukadel.kassambara@gmail.com" id="intref0085">alboukadel.kassambara@gmail.com</ext-link>)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/ggpubr/index.html" id="intref0090">https://cran.r-project.org/web/packages/ggpubr/index.html</ext-link>
                </td>
              </tr>
              <tr>
                <td>ggsignif 0.6.0</td>
                <td>Constantin Ahlmann-Eltze (<ext-link ext-link-type="uri" xlink:href="mailto:artjom31415@googlemail.com" id="intref0095">artjom31415@googlemail.com</ext-link>)</td>
                <td>
                  <ext-link ext-link-type="uri" xlink:href="https://cran.r-project.org/web/packages/ggsignif/index.html" id="intref0100">https://cran.r-project.org/web/packages/ggsignif/index.html</ext-link>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </p>
    </sec>
    <sec id="sec5.2">
      <title>Resource availability</title>
      <sec id="sec5.2.1">
        <title>Lead contact</title>
        <p id="p0130">Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Lu Xie (<ext-link ext-link-type="uri" xlink:href="mailto:luxiex2017@outlook.com" id="intref0105">luxiex2017@outlook.com</ext-link>).</p>
      </sec>
      <sec id="sec5.2.2">
        <title>Materials availability statements</title>
        <p id="p0135">This study did not generate new unique reagents.</p>
      </sec>
      <sec sec-type="data-availability" id="sec5.2.3">
        <title>Data and code availability</title>
        <p id="p0140">
          <list list-type="simple" id="ulist0015">
            <list-item id="u0030">
              <label>•</label>
              <p id="p0145">All the public data including multi-omics data and clinical data for all the samples can be obtained from the ToPP web server (<ext-link ext-link-type="uri" xlink:href="http://www.biostatistics.online/topp/index.php" id="intref0110">http://www.biostatistics.online/topp/index.php</ext-link>).</p>
            </list-item>
            <list-item id="u0035">
              <label>•</label>
              <p id="p0150">All original code has been deposited at <ext-link ext-link-type="uri" xlink:href="https://github.com/kbvstmd/ToPP" id="intref0115">https://github.com/kbvstmd/ToPP</ext-link> and is publicly available as of the date of publication.</p>
            </list-item>
            <list-item id="u0040">
              <label>•</label>
              <p id="p0155">Any additional information required to reanalyze the data reported in this paper is available from the <xref rid="sec5.2.1" ref-type="sec">lead contact</xref> upon request.</p>
            </list-item>
          </list>
        </p>
      </sec>
    </sec>
    <sec id="sec5.3">
      <title>Method details</title>
      <sec id="sec5.3.1">
        <title>Data resource</title>
        <p id="p0160">Multi-omic (Genomic, Transcriptomic, Proteomic, Epigenomic) and clinical data for multiple tumor types from TCGA, ICGA and CPTAC projects were integrated in the ToPP platform (<xref rid="tbl2" ref-type="table">Tables 2</xref> and <xref rid="mmc1" ref-type="supplementary-material">S1</xref>). The genomic data mainly included three types: somatic mutation, Copy Number Variation (CNV) and gene fusion. Somatic mutation data were downloaded from UCSC Xena(<xref rid="bib31" ref-type="bibr">Sanborn et al., 2011</xref>) and ICGC data portal. CNV data were extracted from cBioPortal data portal(<xref rid="bib5" ref-type="bibr">Cerami et al., 2012</xref>) using the R-package ‘cgdsr’ (<ext-link ext-link-type="uri" xlink:href="https://github.com/cBioPortal/cgdsr" id="intref0120">https://github.com/cBioPortal/cgdsr</ext-link>) and ICGC data portal while gene fusion datasets were obtained from TumorFusions(<xref rid="bib43" ref-type="bibr">Xin et al., 2018</xref>). The Transcriptomic data included mRNA expression, miRNA expression and lncRNA expression. The mRNA expression and miRNA expression data were downloaded from UCSC Xena and ICGC data portal, and the LncRNA expression data were collected from TANRIC(<xref rid="bib22" ref-type="bibr">Li et al., 2015</xref>). Proteomic data included reverse phase protein array (RPPA) data and MS-based global proteomic data. The RPPA data were acquired from UCSC Xena and MS proteomic data(isobaric Tags for Relative and Absolute Quantification, iTRAQ) in Breast invasive carcinoma (BRCA) (<xref rid="bib24" ref-type="bibr">Mertins et al., 2016</xref>), Colon adenocarcinoma (COAD) (B. <xref rid="bib45" ref-type="bibr">Zhang et al., 2014</xref>), Ovarian serous cystadenocarcinoma (OV) (<xref rid="bib46" ref-type="bibr">Zhang et al., 2016a</xref>) and Rectum adenocarcinoma (READ) (B. <xref rid="bib45" ref-type="bibr">Zhang et al., 2014</xref>) were extracted from CPTAC using the R-package ‘TCGA-Assembler-2’(<xref rid="bib39" ref-type="bibr">Wei et al., 2018</xref>). Epigenome data (DNA methylation data) were downloaded from UCSC Xena and ICGC data portal. Clinical data were collected from UCSC Xena, cBioPortal data portal and ICGC data portal, which included overall survival(OS), progression-free interval(PFI), disease-specific survival(DSS), disease-free interval(DFI), Relapse Free Survival(RFS) (<xref rid="bib23" ref-type="bibr">Liu et al., 2018</xref>) vital status, tumor stage, age, height, weight, gender, race, lymphatic invasion status, lymph node status, primary tumor pathologic spread, molecular subtypes and immune subtypes (<xref rid="bib17" ref-type="bibr">Hoadley et al., 2018</xref>) (<xref rid="tbl1" ref-type="table">Table 1</xref>). Pan-cancer data were downloaded from PanCanAtlas(<xref rid="bib40" ref-type="bibr">Weinstein et al., 2013</xref>) in UCSC Xena.</p>
      </sec>
      <sec id="sec5.3.2">
        <title>Data preprocessing</title>
        <p id="p0165">The CNV data acquired from cBioPortal data portal were normalized to −2, −1, 0, 1, 2. Here we defined - 2 as CNV loss and 2 for CNV gain. In the meantime, the CNV data were downloaded from ICGC data portal which contains the type information of CNV (gain, loss, etc). Here we only kept the information of CNV for type gain and loss. Somatic mutation data were normalized into 1 and 0, where 1 represents the gene with at least one site mutated, and 0 represents no mutation in this gene. Similarly, gene fusion data was normalized to 1 or 0. Here, 1 indicates the observation of a fusion event in this gene and 0 is the opposite. The methylation value of a gene was determined by the mean beta value of all CpG sites in this gene, and we defined beta values greater than 0.8 as hypermethylation and lower than 0.2 as hypomethylation by default. Users can also customize the thresholds of beta values by selecting hypermethylation or hypomethylation sites in survival analysis. For all of the above data types, we only kept tumor samples. For other data types, such as expression data, we kept both tumor and normal samples.</p>
      </sec>
      <sec id="sec5.3.3">
        <title>Survival analysis</title>
        <sec id="sec5.3.3.1">
          <title>Subgroup selection</title>
          <p id="p0170">With the advance of precision medicine, developing drugs that target a subset of patients with particular features contributing to poor survival can be beneficial to these patients. The function of “subgroup selection” in ToPP is aimed to meet this demand. It mainly includes molecular subgrouping and clinical subgrouping. Molecular subgrouping function allows users to classify mutation subgroups, CNV subgroups and methylation subgroups according to one or more genes to the user’s interest. Clinical subgrouping includes not only the traditional classification such as gender, race or tumor stage, but also the molecular label subgroups, which have been widely applied in clinic, such as the HER2 positive or negative subgroup in breast cancer. Also, the distribution of the clinical features for each molecular stratified group will be show to help identify any potential bias due to some clinical confounding variables.</p>
        </sec>
      </sec>
      <sec id="sec5.3.4">
        <title>Univariate analysis</title>
        <p id="p0175">Univariate analysis was performed with log rank test. For continuous variables such as gene or protein expression, patients can be divided into two groups according to the median value of the variable, quantile or the ‘best-cut’ value. Here, we calculated the log rank p values for the filtering of each sample and kept at least 10% of samples for each group, and the cut point with the lowest p value was represented as the “best-cut”. For categorical variables such as somatic mutation, CNV or gene fusion, patients were divided into two groups by the binarized classification. Kaplan-Meier (KM) survival curves(<xref rid="bib20" ref-type="bibr">Kleinbaum and Klein, 2012</xref>) were then drawn by the divided groups, the hazard ratio and the 95% confidence interval information were also included in the survival plot.</p>
      </sec>
      <sec id="sec5.3.5">
        <title>Combination analysis</title>
        <p id="p0180">Combination analysis is to analyze the prognosis effects by considering two features. These two features can be in the same level of data such as the expression of two genes, or they can be in different levels. For instance, if a researcher wants to know the prognostic impact of gene A expression in combination with gene B mutant. Then, all the patients were divided into four groups (high expression + mutation group, high expression + wild type group, low expression + mutation group and low expression + wild type group) according to the threshold of two features, and then log-rank test was performed to test whether there was significant difference between any of two groups, separately. Co-inactivation of one gene pair which results in better survival may provide evidence for synthetic lethality interaction prediction(<xref rid="bib21" ref-type="bibr">Lee et al., 2018</xref>).</p>
      </sec>
      <sec id="sec5.3.6">
        <title>Multivariate analysis and prognostic modeling</title>
        <p id="p0185">Cox regression (or Cox proportional hazards model) is used for multivariate analysis(<xref rid="bib7" ref-type="bibr">Christensen, 1987</xref>). When constructing a prognostic model, we firstly fit a naive Cox model including all covariates. Then, redundant or irrelevant variables from the model should be removed. Interaction between covariates and time-dependent covariates should also be considered in the modeling process (<xref rid="bib2" ref-type="bibr">Austin et al., 2020</xref>). Therefore, stepwise regression is performed to select the variables of the model and is evaluated by the Akaike information criterion (AIC) value. For diagnostic model, we mainly included the following three aspects: 1) testing the proportional hazards (PH) assumption, 2) examining influential observations (or outliers), 3) detecting nonlinearity in relationship between the log hazard and the covariates. In order to test the model assumptions, residuals method was used. The common residuals for the Cox model included: 1) Schoenfeld residuals to test the proportional hazards assumption; 2) Martingale residual to assess nonlinearity; 3) Deviance residual (symmetric transformation of the martinguale residuals), to examine influential observations(<xref rid="bib44" ref-type="bibr">Xue and Schifano, 2017</xref>). Covariates conversion such as nonlinear transformations should be performed if it is necessary. Finally, we used Concordance index (C-index) (<xref rid="bib14" ref-type="bibr">Harrell et al., 1996</xref>) to evaluate the effect of the model.</p>
      </sec>
      <sec id="sec5.3.7">
        <title>Pan-cancer analysis</title>
        <p id="p0190">In order to reduce the impact of tissue specificity on the data, we used a specially standardized dataset named the Pan-Cancer Atlas(<xref rid="bib17" ref-type="bibr">Hoadley et al., 2018</xref>), which has normalized and removed batch effects of the data, making the data comparable. In addition, since the expression of genes in various types of tumors may be quite different, when doing the pan-cancer prognostic analysis, we first divided the patients into high gene expression group and low gene expression group according to the median gene expression in each type of tumor, separately. Then, all the high expression samples were combined as the pan-cancer high group, so is the low expression samples. After that the log rank test was performed between these two groups.</p>
      </sec>
    </sec>
    <sec id="sec5.4">
      <title>Quantification and statistical analysis</title>
      <p id="p0195">The ToPP web interface was developed using HTML5 and PHP script (version 7.0.12) in the Bootstrap framework. JavaScript and jQuery were also used to perform dynamic web services with js library such as DataTables.js and select2.js. The database was implemented in MySQL (version 5.7.17) and deployed in Apache web server running on the CentOS 6.5 system. Data preprocessing and data analyses were performed by the R scripts (version 3.5.0) with several R packages (rms v5.4.1, survminer v0.4.6, stringr v1.4.0, data.table v1.12.8, dplyr v0.8.5, forestplot v1.9, ggpubr v0.2.5, ggsignif v0.6.0). Wilcoxon rank sum test was used to compare two groups, and p &lt; 0.05 was considered as significant difference. Significance levels p &lt; 0.05, p &lt; 0.01 and p &lt; 0.001 are noted using asterisks ∗, ∗∗, and ∗∗∗, respectively.</p>
    </sec>
  </sec>
</body>
<back>
  <ref-list id="cebib0010">
    <title>References</title>
    <ref id="bib1">
      <element-citation publication-type="journal" id="sref1">
        <person-group person-group-type="author">
          <name>
            <surname>Anaya</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs</article-title>
        <source>PeerJ Comput. Sci.</source>
        <volume>2</volume>
        <year>2016</year>
        <fpage>e67</fpage>
        <pub-id pub-id-type="doi">10.7287/peerj.preprints.1780v1</pub-id>
      </element-citation>
    </ref>
    <ref id="bib2">
      <element-citation publication-type="journal" id="sref2">
        <person-group person-group-type="author">
          <name>
            <surname>Austin</surname>
            <given-names>P.C.</given-names>
          </name>
          <name>
            <surname>Latouche</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Fine</surname>
            <given-names>J.P.</given-names>
          </name>
        </person-group>
        <article-title>A review of the use of time-varying covariates in the Fine-Gray subdistribution hazard competing risk regression model</article-title>
        <source>Stat. Med.</source>
        <volume>39</volume>
        <year>2020</year>
        <fpage>103</fpage>
        <lpage>113</lpage>
        <pub-id pub-id-type="doi">10.1002/sim.8399</pub-id>
        <pub-id pub-id-type="pmid">31660633</pub-id>
      </element-citation>
    </ref>
    <ref id="bib3">
      <element-citation publication-type="book" id="sref3">
        <person-group person-group-type="author">
          <name>
            <surname>Banfalvi</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <part-title>Homeostasis - Tumor - Metastasis</part-title>
        <year>2014</year>
        <publisher-name>Springer</publisher-name>
      </element-citation>
    </ref>
    <ref id="bib4">
      <element-citation publication-type="journal" id="sref4">
        <person-group person-group-type="author">
          <name>
            <surname>Beck</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Rodriguez-Vargas</surname>
            <given-names>J.M.</given-names>
          </name>
          <name>
            <surname>Boehler</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Robert</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Heyer</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Hanini</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Gauthier</surname>
            <given-names>L.R.</given-names>
          </name>
          <name>
            <surname>Tissier</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Schreiber</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Elofsson</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>'PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers</article-title>
        <source>Cell Death Differ.</source>
        <volume>26</volume>
        <year>2019</year>
        <fpage>1615</fpage>
        <lpage>1630</lpage>
        <pub-id pub-id-type="doi">10.1038/s41418-018-0233-1</pub-id>
        <pub-id pub-id-type="pmid">30442946</pub-id>
      </element-citation>
    </ref>
    <ref id="bib5">
      <element-citation publication-type="journal" id="sref5">
        <person-group person-group-type="author">
          <name>
            <surname>Cerami</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Dogrusoz</surname>
            <given-names>U.</given-names>
          </name>
          <name>
            <surname>Gross</surname>
            <given-names>B.E.</given-names>
          </name>
          <name>
            <surname>Sumer</surname>
            <given-names>S.O.</given-names>
          </name>
          <name>
            <surname>Aksoy</surname>
            <given-names>B.A.</given-names>
          </name>
          <name>
            <surname>Jacobsen</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Byrne</surname>
            <given-names>C.J.</given-names>
          </name>
          <name>
            <surname>Heuer</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Larsson</surname>
            <given-names>E.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title>
        <source>Cancer Discov.</source>
        <volume>2</volume>
        <year>2012</year>
        <fpage>401</fpage>
        <lpage>404</lpage>
        <pub-id pub-id-type="doi">10.1158/2159-8290.cd-12-0095</pub-id>
        <pub-id pub-id-type="pmid">22588877</pub-id>
      </element-citation>
    </ref>
    <ref id="bib6">
      <element-citation publication-type="journal" id="sref6">
        <person-group person-group-type="author">
          <name>
            <surname>Chen</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X.</given-names>
          </name>
        </person-group>
        <article-title>miRDB: an online database for prediction of functional microRNA targets</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>48</volume>
        <year>2020</year>
        <fpage>D127</fpage>
        <lpage>D131</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkz757</pub-id>
        <pub-id pub-id-type="pmid">31504780</pub-id>
      </element-citation>
    </ref>
    <ref id="bib7">
      <element-citation publication-type="journal" id="sref7">
        <person-group person-group-type="author">
          <name>
            <surname>Christensen</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>Multivariate survival analysis using Cox's regression model</article-title>
        <source>Hepatology</source>
        <volume>7</volume>
        <year>1987</year>
        <fpage>1346</fpage>
        <lpage>1358</lpage>
        <pub-id pub-id-type="doi">10.1002/hep.1840070628</pub-id>
        <pub-id pub-id-type="pmid">3679094</pub-id>
      </element-citation>
    </ref>
    <ref id="bib8">
      <element-citation publication-type="journal" id="sref8">
        <person-group person-group-type="author">
          <name>
            <surname>Deng</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Development and validation of an IDH1-associated immune prognostic signature for diffuse lower-grade glioma</article-title>
        <source>Front. Oncol.</source>
        <volume>9</volume>
        <year>2019</year>
        <fpage>1310</fpage>
        <pub-id pub-id-type="doi">10.3389/fonc.2019.01310</pub-id>
        <pub-id pub-id-type="pmid">31824866</pub-id>
      </element-citation>
    </ref>
    <ref id="bib9">
      <element-citation publication-type="journal" id="sref9">
        <person-group person-group-type="author">
          <name>
            <surname>Fujimoto</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Furuta</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Totoki</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Tsunoda</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Kato</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Shiraishi</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Tanaka</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Taniguchi</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Kawakami</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ueno</surname>
            <given-names>M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer</article-title>
        <source>Nat. Genet.</source>
        <volume>48</volume>
        <year>2016</year>
        <fpage>500</fpage>
        <lpage>509</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.3547</pub-id>
        <pub-id pub-id-type="pmid">27064257</pub-id>
      </element-citation>
    </ref>
    <ref id="bib10">
      <element-citation publication-type="journal" id="sref10">
        <person-group person-group-type="author">
          <name>
            <surname>Gossage</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Eisen</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Maher</surname>
            <given-names>E.R.</given-names>
          </name>
        </person-group>
        <article-title>VHL, the story of a tumour suppressor gene</article-title>
        <source>Nat. Rev. Cancer</source>
        <volume>15</volume>
        <year>2015</year>
        <fpage>55</fpage>
        <lpage>64</lpage>
        <pub-id pub-id-type="doi">10.1038/nrc3844</pub-id>
        <pub-id pub-id-type="pmid">25533676</pub-id>
      </element-citation>
    </ref>
    <ref id="bib11">
      <element-citation publication-type="journal" id="sref11">
        <person-group person-group-type="author">
          <name>
            <surname>Grundy</surname>
            <given-names>G.J.</given-names>
          </name>
          <name>
            <surname>Polo</surname>
            <given-names>L.M.</given-names>
          </name>
          <name>
            <surname>Zeng</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Rulten</surname>
            <given-names>S.L.</given-names>
          </name>
          <name>
            <surname>Hoch</surname>
            <given-names>N.C.</given-names>
          </name>
          <name>
            <surname>Paomephan</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Sweet</surname>
            <given-names>S.M.</given-names>
          </name>
          <name>
            <surname>Thorne</surname>
            <given-names>A.W.</given-names>
          </name>
          <name>
            <surname>Oliver</surname>
            <given-names>A.W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2B(Glu2)</article-title>
        <source>Nat. Commun.</source>
        <volume>7</volume>
        <year>2016</year>
        <fpage>12404</fpage>
        <pub-id pub-id-type="doi">10.1038/ncomms12404</pub-id>
        <pub-id pub-id-type="pmid">27530147</pub-id>
      </element-citation>
    </ref>
    <ref id="bib12">
      <element-citation publication-type="journal" id="sref12">
        <person-group person-group-type="author">
          <name>
            <surname>Hansebout</surname>
            <given-names>R.R.</given-names>
          </name>
          <name>
            <surname>Cornacchi</surname>
            <given-names>S.D.</given-names>
          </name>
          <name>
            <surname>Haines</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Goldsmith</surname>
            <given-names>C.H.</given-names>
          </name>
        </person-group>
        <article-title>How to use an article about prognosis</article-title>
        <source>Can. J. Surg.</source>
        <volume>52</volume>
        <year>2009</year>
        <fpage>328</fpage>
        <lpage>336</lpage>
        <pub-id pub-id-type="pmid">19680521</pub-id>
      </element-citation>
    </ref>
    <ref id="bib13">
      <element-citation publication-type="journal" id="sref13">
        <person-group person-group-type="author">
          <name>
            <surname>Hao</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ouyang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Qin</surname>
            <given-names>G.</given-names>
          </name>
        </person-group>
        <article-title>Investigation of lipid metabolism dysregulation and the effects on immune microenvironments in pan-cancer using multiple omics data</article-title>
        <source>BMC Bioinf.</source>
        <volume>20</volume>
        <issue>Suppl 7</issue>
        <year>2019</year>
        <fpage>195</fpage>
        <pub-id pub-id-type="doi">10.1186/s12859-019-2734-4</pub-id>
      </element-citation>
    </ref>
    <ref id="bib14">
      <element-citation publication-type="journal" id="sref14">
        <person-group person-group-type="author">
          <name>
            <surname>Harrell</surname>
            <given-names>F.E.</given-names>
            <suffix>Jr.</suffix>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>K.L.</given-names>
          </name>
          <name>
            <surname>Mark</surname>
            <given-names>D.B.</given-names>
          </name>
        </person-group>
        <article-title>Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors</article-title>
        <source>Stat. Med.</source>
        <volume>15</volume>
        <year>1996</year>
        <fpage>361</fpage>
        <lpage>387</lpage>
        <pub-id pub-id-type="doi">10.1002/(sici)1097-0258(19960229)15:4&lt;361::aid-sim168&gt;3.0.co;2-4</pub-id>
        <pub-id pub-id-type="pmid">8668867</pub-id>
      </element-citation>
    </ref>
    <ref id="bib15">
      <element-citation publication-type="journal" id="sref15">
        <person-group person-group-type="author">
          <name>
            <surname>Hernandez-Quiles</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Broekema</surname>
            <given-names>M.F.</given-names>
          </name>
          <name>
            <surname>Kalkhoven</surname>
            <given-names>E.</given-names>
          </name>
        </person-group>
        <article-title>PPARgamma in metabolism, immunity, and cancer: unified and diverse mechanisms of action</article-title>
        <source>Front. Endocrinol.</source>
        <volume>12</volume>
        <year>2021</year>
        <fpage>624112</fpage>
        <pub-id pub-id-type="doi">10.3389/fendo.2021.624112</pub-id>
      </element-citation>
    </ref>
    <ref id="bib16">
      <element-citation publication-type="journal" id="sref16">
        <person-group person-group-type="author">
          <name>
            <surname>Herranz</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Dave</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Millanes-Romero</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Pascual-Reguant</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Morey</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>DÃ-az</surname>
            <given-names>V.M.</given-names>
          </name>
          <name>
            <surname>LÃ³renz-FonfrÃ-a</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Gutierrez-Gallego</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>JerÃ³nimo</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Iturbide</surname>
            <given-names>A.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Lysyl oxidase-like 2 (LOXL2) oxidizes trimethylated lysine 4 in histone H3</article-title>
        <source>FEBS J.</source>
        <volume>283</volume>
        <year>2016</year>
        <fpage>4263</fpage>
        <lpage>4273</lpage>
        <pub-id pub-id-type="doi">10.1111/febs.13922</pub-id>
        <pub-id pub-id-type="pmid">27735137</pub-id>
      </element-citation>
    </ref>
    <ref id="bib17">
      <element-citation publication-type="journal" id="sref17">
        <person-group person-group-type="author">
          <name>
            <surname>Hoadley</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Yau</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Hinoue</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Wolf</surname>
            <given-names>D.M.</given-names>
          </name>
          <name>
            <surname>Lazar</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Drill</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Shen</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Taylor</surname>
            <given-names>A.M.</given-names>
          </name>
          <name>
            <surname>Cherniack</surname>
            <given-names>A.D.</given-names>
          </name>
          <name>
            <surname>Thorsson</surname>
            <given-names>V.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cell-of-Origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer</article-title>
        <source>Cell</source>
        <volume>173</volume>
        <year>2018</year>
        <fpage>291</fpage>
        <lpage>304.e6</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2018.03.022</pub-id>
        <pub-id pub-id-type="pmid">29625048</pub-id>
      </element-citation>
    </ref>
    <ref id="bib18">
      <element-citation publication-type="journal" id="sref18">
        <person-group person-group-type="author">
          <name>
            <surname>Jang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Seo</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>CaPSSA: visual evaluation of cancer biomarker genes for patient stratification and survival analysis using mutation and expression data</article-title>
        <source>Bioinformatics</source>
        <volume>35</volume>
        <year>2019</year>
        <fpage>5341</fpage>
        <lpage>5343</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btz516</pub-id>
        <pub-id pub-id-type="pmid">31228188</pub-id>
      </element-citation>
    </ref>
    <ref id="bib19">
      <element-citation publication-type="journal" id="sref19">
        <person-group person-group-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>J.T.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Weiss</surname>
            <given-names>H.L.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Evers</surname>
            <given-names>B.M.</given-names>
          </name>
        </person-group>
        <article-title>Regulation of ketogenic enzyme HMGCS2 by wnt/Î<sup>2</sup>-catenin/PPARÎ³ pathway in intestinal cells</article-title>
        <source>Cells</source>
        <volume>8</volume>
        <year>2019</year>
        <fpage>1106</fpage>
        <pub-id pub-id-type="doi">10.3390/cells8091106</pub-id>
      </element-citation>
    </ref>
    <ref id="bib20">
      <element-citation publication-type="book" id="sref20">
        <person-group person-group-type="author">
          <name>
            <surname>Kleinbaum</surname>
            <given-names>D.G.</given-names>
          </name>
          <name>
            <surname>Klein</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <part-title>Kaplan-meier Survival Curves and the Log-Rank Test <italic>Survival Analysis: A Self-Learning Text</italic></part-title>
        <year>2012</year>
        <publisher-name>Springer New York</publisher-name>
        <fpage>55</fpage>
        <lpage>96</lpage>
      </element-citation>
    </ref>
    <ref id="bib21">
      <element-citation publication-type="journal" id="sref21">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>J.S.</given-names>
          </name>
          <name>
            <surname>Das</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Jerby-Arnon</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Arafeh</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Auslander</surname>
            <given-names>N.</given-names>
          </name>
          <name>
            <surname>Davidson</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>McGarry</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>James</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Amzallag</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Park</surname>
            <given-names>S.G.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Harnessing synthetic lethality to predict the response to cancer treatment</article-title>
        <source>Nat. Commun.</source>
        <volume>9</volume>
        <year>2018</year>
        <fpage>2546</fpage>
        <pub-id pub-id-type="doi">10.1038/s41467-018-04647-1</pub-id>
        <pub-id pub-id-type="pmid">29959327</pub-id>
      </element-citation>
    </ref>
    <ref id="bib22">
      <element-citation publication-type="journal" id="sref22">
        <person-group person-group-type="author">
          <name>
            <surname>Li</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Han</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Roebuck</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Diao</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Yuan</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Weinstein</surname>
            <given-names>J.N.</given-names>
          </name>
          <name>
            <surname>Liang</surname>
            <given-names>H.</given-names>
          </name>
        </person-group>
        <article-title>TANRIC: an interactive open platform to explore the function of lncRNAs in cancer</article-title>
        <source>Cancer Res.</source>
        <volume>75</volume>
        <year>2015</year>
        <fpage>3728</fpage>
        <lpage>3737</lpage>
        <pub-id pub-id-type="doi">10.1158/0008-5472.can-15-0273</pub-id>
        <pub-id pub-id-type="pmid">26208906</pub-id>
      </element-citation>
    </ref>
    <ref id="bib23">
      <element-citation publication-type="journal" id="sref23">
        <person-group person-group-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lichtenberg</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Hoadley</surname>
            <given-names>K.A.</given-names>
          </name>
          <name>
            <surname>Poisson</surname>
            <given-names>L.M.</given-names>
          </name>
          <name>
            <surname>Lazar</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Cherniack</surname>
            <given-names>A.D.</given-names>
          </name>
          <name>
            <surname>Kovatich</surname>
            <given-names>A.J.</given-names>
          </name>
          <name>
            <surname>Benz</surname>
            <given-names>C.C.</given-names>
          </name>
          <name>
            <surname>Levine</surname>
            <given-names>D.A.</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>A.V.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics</article-title>
        <source>Cell</source>
        <volume>173</volume>
        <year>2018</year>
        <fpage>400</fpage>
        <lpage>416.e11</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2018.02.052</pub-id>
        <pub-id pub-id-type="pmid">29625055</pub-id>
      </element-citation>
    </ref>
    <ref id="bib24">
      <element-citation publication-type="journal" id="sref24">
        <person-group person-group-type="author">
          <name>
            <surname>Mertins</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Mani</surname>
            <given-names>D.R.</given-names>
          </name>
          <name>
            <surname>Ruggles</surname>
            <given-names>K.V.</given-names>
          </name>
          <name>
            <surname>Gillette</surname>
            <given-names>M.A.</given-names>
          </name>
          <name>
            <surname>Clauser</surname>
            <given-names>K.R.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>P.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Qiao</surname>
            <given-names>J.W.</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Petralia</surname>
            <given-names>F.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomics connects somatic mutations to signalling in breast cancer</article-title>
        <source>Nature</source>
        <volume>534</volume>
        <year>2016</year>
        <fpage>55</fpage>
        <lpage>62</lpage>
        <pub-id pub-id-type="doi">10.1038/nature18003</pub-id>
        <pub-id pub-id-type="pmid">27251275</pub-id>
      </element-citation>
    </ref>
    <ref id="bib25">
      <element-citation publication-type="journal" id="sref25">
        <person-group person-group-type="author">
          <name>
            <surname>Mizuno</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Kitada</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Nakai</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Sarai</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>PrognoScan: a new database for meta-analysis of the prognostic value of genes</article-title>
        <source>BMC Med. Genom.</source>
        <volume>2</volume>
        <year>2009</year>
        <fpage>18</fpage>
        <pub-id pub-id-type="doi">10.1186/1755-8794-2-18</pub-id>
      </element-citation>
    </ref>
    <ref id="bib26">
      <element-citation publication-type="journal" id="sref26">
        <person-group person-group-type="author">
          <name>
            <surname>Modhukur</surname>
            <given-names>V.</given-names>
          </name>
          <name>
            <surname>Iljasenko</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Metsalu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Lokk</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Laisk-Podar</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Vilo</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>MethSurv: a web tool to perform multivariable survival analysis using DNA methylation data</article-title>
        <source>Epigenomics</source>
        <volume>10</volume>
        <year>2018</year>
        <fpage>277</fpage>
        <lpage>288</lpage>
        <pub-id pub-id-type="doi">10.2217/epi-2017-0118</pub-id>
        <pub-id pub-id-type="pmid">29264942</pub-id>
      </element-citation>
    </ref>
    <ref id="bib27">
      <element-citation publication-type="journal" id="sref27">
        <person-group person-group-type="author">
          <name>
            <surname>Montazeri</surname>
            <given-names>A.</given-names>
          </name>
        </person-group>
        <article-title>Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008</article-title>
        <source>Health Qual. Life Outcome</source>
        <volume>7</volume>
        <year>2009</year>
        <fpage>102</fpage>
        <pub-id pub-id-type="doi">10.1186/1477-7525-7-102</pub-id>
      </element-citation>
    </ref>
    <ref id="bib28">
      <element-citation publication-type="journal" id="sref28">
        <person-group person-group-type="author">
          <name>
            <surname>Noh</surname>
            <given-names>K.H.</given-names>
          </name>
          <name>
            <surname>Kang</surname>
            <given-names>H.M.</given-names>
          </name>
          <name>
            <surname>Yoo</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Min</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Lim</surname>
            <given-names>J.H.</given-names>
          </name>
          <name>
            <surname>Jung</surname>
            <given-names>C.R.</given-names>
          </name>
        </person-group>
        <article-title>Ubiquitination of PPAR-gamma by pVHL inhibits ACLY expression and lipid metabolism, is implicated in tumor progression</article-title>
        <source>Metab. Clin. Exp.</source>
        <volume>110</volume>
        <year>2020</year>
        <fpage>154302</fpage>
        <pub-id pub-id-type="doi">10.1016/j.metabol.2020.154302</pub-id>
        <pub-id pub-id-type="pmid">32589900</pub-id>
      </element-citation>
    </ref>
    <ref id="bib29">
      <element-citation publication-type="journal" id="sref29">
        <person-group person-group-type="author">
          <name>
            <surname>Núñez</surname>
            <given-names>E.</given-names>
          </name>
          <name>
            <surname>Steyerberg</surname>
            <given-names>E.W.</given-names>
          </name>
          <name>
            <surname>Núñez</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Regression modeling strategies</article-title>
        <source>Rev. Española Cardiol. (English Edition)</source>
        <volume>64</volume>
        <year>2011</year>
        <fpage>501</fpage>
        <lpage>507</lpage>
        <pub-id pub-id-type="doi">10.1016/j.rec.2011.01.017</pub-id>
      </element-citation>
    </ref>
    <ref id="bib30">
      <element-citation publication-type="journal" id="sref30">
        <person-group person-group-type="author">
          <name>
            <surname>Raineri</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Mellor</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>IDH1: linking metabolism and epigenetics</article-title>
        <source>Front. Genet.</source>
        <volume>9</volume>
        <year>2018</year>
        <fpage>493</fpage>
        <pub-id pub-id-type="doi">10.3389/fgene.2018.00493</pub-id>
        <pub-id pub-id-type="pmid">30405699</pub-id>
      </element-citation>
    </ref>
    <ref id="bib31">
      <element-citation publication-type="journal" id="sref31">
        <person-group person-group-type="author">
          <name>
            <surname>Sanborn</surname>
            <given-names>J.Z.</given-names>
          </name>
          <name>
            <surname>Benz</surname>
            <given-names>S.C.</given-names>
          </name>
          <name>
            <surname>Craft</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Szeto</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Kober</surname>
            <given-names>K.M.</given-names>
          </name>
          <name>
            <surname>Meyer</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Vaske</surname>
            <given-names>C.J.</given-names>
          </name>
          <name>
            <surname>Goldman</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Smith</surname>
            <given-names>K.E.</given-names>
          </name>
          <name>
            <surname>Kuhn</surname>
            <given-names>R.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The UCSC cancer genomics browser: update 2011</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>39</volume>
        <year>2011</year>
        <fpage>D951</fpage>
        <lpage>D959</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkq1113</pub-id>
        <comment>Database issue</comment>
        <pub-id pub-id-type="pmid">21059681</pub-id>
      </element-citation>
    </ref>
    <ref id="bib32">
      <element-citation publication-type="journal" id="sref32">
        <person-group person-group-type="author">
          <name>
            <surname>Sanchez-Vega</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Mina</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Armenia</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Chatila</surname>
            <given-names>W.K.</given-names>
          </name>
          <name>
            <surname>Luna</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>La</surname>
            <given-names>K.C.</given-names>
          </name>
          <name>
            <surname>Dimitriadoy</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>D.L.</given-names>
          </name>
          <name>
            <surname>Kantheti</surname>
            <given-names>H.S.</given-names>
          </name>
          <name>
            <surname>Saghafinia</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Oncogenic signaling pathways in the cancer genome Atlas</article-title>
        <source>Cell</source>
        <volume>173</volume>
        <year>2018</year>
        <fpage>321</fpage>
        <lpage>337.e10</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2018.03.035</pub-id>
        <pub-id pub-id-type="pmid">29625050</pub-id>
      </element-citation>
    </ref>
    <ref id="bib33">
      <element-citation publication-type="journal" id="sref33">
        <person-group person-group-type="author">
          <name>
            <surname>Sharif-Askari</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Amrein</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Aloyz</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Panasci</surname>
            <given-names>L.</given-names>
          </name>
        </person-group>
        <article-title>PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines</article-title>
        <source>Breast Cancer Res. Treat.</source>
        <volume>172</volume>
        <year>2018</year>
        <fpage>23</fpage>
        <lpage>32</lpage>
        <pub-id pub-id-type="doi">10.1007/s10549-018-4888-6</pub-id>
        <pub-id pub-id-type="pmid">30039287</pub-id>
      </element-citation>
    </ref>
    <ref id="bib34">
      <element-citation publication-type="journal" id="sref34">
        <person-group person-group-type="author">
          <name>
            <surname>Sung</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Ferlay</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Siegel</surname>
            <given-names>R.L.</given-names>
          </name>
          <name>
            <surname>Laversanne</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Soerjomataram</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Jemal</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Bray</surname>
            <given-names>F.</given-names>
          </name>
        </person-group>
        <article-title>Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title>
        <source>CA Cancer J. Clin.</source>
        <volume>71</volume>
        <year>2021</year>
        <fpage>209</fpage>
        <lpage>249</lpage>
        <pub-id pub-id-type="doi">10.3322/caac.21660</pub-id>
        <pub-id pub-id-type="pmid">33538338</pub-id>
      </element-citation>
    </ref>
    <ref id="bib35">
      <element-citation publication-type="journal" id="sref35">
        <person-group person-group-type="author">
          <name>
            <surname>Tang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Kang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z.</given-names>
          </name>
        </person-group>
        <article-title>GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>45</volume>
        <year>2017</year>
        <fpage>W98</fpage>
        <lpage>W102</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx247</pub-id>
        <pub-id pub-id-type="pmid">28407145</pub-id>
      </element-citation>
    </ref>
    <ref id="bib36">
      <element-citation publication-type="journal" id="sref36">
        <person-group person-group-type="author">
          <name>
            <surname>Venneti</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Felicella</surname>
            <given-names>M.M.</given-names>
          </name>
          <name>
            <surname>Coyne</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Phillips</surname>
            <given-names>J.J.</given-names>
          </name>
          <name>
            <surname>Gorovets</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Huse</surname>
            <given-names>J.T.</given-names>
          </name>
          <name>
            <surname>Kofler</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Tihan</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Sullivan</surname>
            <given-names>L.M.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>'Histone 3 lysine 9 trimethylation is differentially associated with isocitrate dehydrogenase mutations in oligodendrogliomas and high-grade astrocytomas</article-title>
        <source>J. Neuropathol. Exp. Neurol.</source>
        <volume>72</volume>
        <year>2013</year>
        <fpage>298</fpage>
        <lpage>306</lpage>
        <pub-id pub-id-type="doi">10.1097/NEN.0b013e3182898113</pub-id>
        <pub-id pub-id-type="pmid">23481705</pub-id>
      </element-citation>
    </ref>
    <ref id="bib37">
      <element-citation publication-type="journal" id="sref37">
        <person-group person-group-type="author">
          <name>
            <surname>VilÃ -Brau</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>De Sousa-Coelho</surname>
            <given-names>A.L.</given-names>
          </name>
          <name>
            <surname>Mayordomo</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Haro</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Marrero</surname>
            <given-names>P.F.</given-names>
          </name>
        </person-group>
        <article-title>Human HMGCS2 regulates mitochondrial fatty acid oxidation and FGF21 expression in HepG2 cell line</article-title>
        <source>J. Biol. Chem.</source>
        <volume>286</volume>
        <year>2011</year>
        <fpage>20423</fpage>
        <lpage>20430</lpage>
        <pub-id pub-id-type="doi">10.1074/jbc.M111.235044</pub-id>
        <pub-id pub-id-type="pmid">21502324</pub-id>
      </element-citation>
    </ref>
    <ref id="bib38">
      <element-citation publication-type="journal" id="sref38">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Bao</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>'miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1</article-title>
        <source>Cell Death Dis.</source>
        <volume>9</volume>
        <year>2018</year>
        <fpage>447</fpage>
        <pub-id pub-id-type="doi">10.1038/s41419-018-0390-7</pub-id>
        <pub-id pub-id-type="pmid">29670086</pub-id>
      </element-citation>
    </ref>
    <ref id="bib39">
      <element-citation publication-type="journal" id="sref39">
        <person-group person-group-type="author">
          <name>
            <surname>Wei</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Jin</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Ji</surname>
            <given-names>Y.</given-names>
          </name>
        </person-group>
        <article-title>TCGA-assembler 2: software pipeline for retrieval and processing of TCGA/CPTAC data</article-title>
        <source>Bioinformatics</source>
        <volume>34</volume>
        <year>2018</year>
        <fpage>1615</fpage>
        <lpage>1617</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btx812</pub-id>
        <pub-id pub-id-type="pmid">29272348</pub-id>
      </element-citation>
    </ref>
    <ref id="bib40">
      <element-citation publication-type="journal" id="sref40">
        <person-group person-group-type="author">
          <name>
            <surname>Weinstein</surname>
            <given-names>J.N.</given-names>
          </name>
          <name>
            <surname>Collisson</surname>
            <given-names>E.A.</given-names>
          </name>
          <name>
            <surname>Mills</surname>
            <given-names>G.B.</given-names>
          </name>
          <name>
            <surname>Shaw</surname>
            <given-names>K.R.</given-names>
          </name>
          <name>
            <surname>Ozenberger</surname>
            <given-names>B.A.</given-names>
          </name>
          <name>
            <surname>Ellrott</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Shmulevich</surname>
            <given-names>I.</given-names>
          </name>
          <name>
            <surname>Sander</surname>
            <given-names>C.</given-names>
          </name>
          <name>
            <surname>Stuart</surname>
            <given-names>J.M.</given-names>
          </name>
        </person-group>
        <article-title>The cancer genome Atlas pan-cancer analysis project</article-title>
        <source>Nat. Genet.</source>
        <volume>45</volume>
        <year>2013</year>
        <fpage>1113</fpage>
        <lpage>1120</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.2764</pub-id>
        <pub-id pub-id-type="pmid">24071849</pub-id>
      </element-citation>
    </ref>
    <ref id="bib41">
      <element-citation publication-type="book" id="sref41">
        <person-group person-group-type="author">
          <name>
            <surname>Whetstine</surname>
            <given-names>J.R.</given-names>
          </name>
        </person-group>
        <part-title>Chapter 287 - histone methylation: chemically inert but chromatin dynamic</part-title>
        <person-group person-group-type="editor">
          <name>
            <surname>Bradshaw</surname>
            <given-names>R.A.</given-names>
          </name>
          <name>
            <surname>Dennis</surname>
            <given-names>E.A.</given-names>
          </name>
        </person-group>
        <source>Handbook of Cell Signaling</source>
        <edition>Second Edition</edition>
        <year>2010</year>
        <publisher-name>Academic Press</publisher-name>
        <fpage>2389</fpage>
        <lpage>2397</lpage>
      </element-citation>
    </ref>
    <ref id="bib42">
      <element-citation publication-type="journal" id="sref42">
        <person-group person-group-type="author">
          <name>
            <surname>Wickham</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Averick</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Bryan</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>W.</given-names>
          </name>
          <name>
            <surname>McGowan</surname>
            <given-names>L.D.A.</given-names>
          </name>
          <name>
            <surname>FranÃ§ois</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Grolemund</surname>
            <given-names>G.</given-names>
          </name>
          <name>
            <surname>Hayes</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Henry</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Hester</surname>
            <given-names>J.</given-names>
          </name>
        </person-group>
        <article-title>Welcome to the tidyverse</article-title>
        <source>J. Open Source Softw.</source>
        <volume>4</volume>
        <year>2019</year>
        <fpage>1686</fpage>
        <pub-id pub-id-type="doi">10.21105/joss.01686</pub-id>
      </element-citation>
    </ref>
    <ref id="bib43">
      <element-citation publication-type="journal" id="sref43">
        <person-group person-group-type="author">
          <name>
            <surname>Xin</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Ming</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Floris</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Samirkumar</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Kosuke</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Lang</surname>
            <given-names>F.M.</given-names>
          </name>
          <name>
            <surname>Emmanuel</surname>
            <given-names>M.L.</given-names>
          </name>
          <name>
            <surname>Hyun</surname>
            <given-names>L.S.</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>S.</given-names>
          </name>
        </person-group>
        <article-title>TumorFusions: an integrative resource for cancer-associated transcript fusions</article-title>
        <source>Nucleic Acids Res.</source>
        <volume>46</volume>
        <year>2018</year>
        <fpage>D1144</fpage>
        <lpage>D1149</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1018</pub-id>
        <pub-id pub-id-type="pmid">29099951</pub-id>
      </element-citation>
    </ref>
    <ref id="bib44">
      <element-citation publication-type="journal" id="sref44">
        <person-group person-group-type="author">
          <name>
            <surname>Xue</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Schifano</surname>
            <given-names>E.D.</given-names>
          </name>
        </person-group>
        <article-title>Diagnostics for the Cox model</article-title>
        <source>Commun. Stat. Appl. Methods</source>
        <volume>24</volume>
        <year>2017</year>
        <fpage>583</fpage>
        <lpage>604</lpage>
        <pub-id pub-id-type="doi">10.29220/CSAM.2017.24.6.583</pub-id>
      </element-citation>
    </ref>
    <ref id="bib45">
      <element-citation publication-type="journal" id="sref45">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>Q.</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Chambers</surname>
            <given-names>M.C.</given-names>
          </name>
          <name>
            <surname>Zimmerman</surname>
            <given-names>L.J.</given-names>
          </name>
          <name>
            <surname>Shaddox</surname>
            <given-names>K.F.</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>S.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic characterization of human colon and rectal cancer</article-title>
        <source>Nature</source>
        <volume>513</volume>
        <year>2014</year>
        <fpage>382</fpage>
        <lpage>387</lpage>
        <pub-id pub-id-type="doi">10.1038/nature13438</pub-id>
        <pub-id pub-id-type="pmid">25043054</pub-id>
      </element-citation>
    </ref>
    <ref id="bib46">
      <element-citation publication-type="journal" id="sref46">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Chan</surname>
            <given-names>D.W.</given-names>
          </name>
          <name>
            <surname>Oberti</surname>
            <given-names>M.</given-names>
          </name>
        </person-group>
        <article-title>Integrated proteogenomic characterization of human high-grade serous ovarian cancer</article-title>
        <source>Cell</source>
        <volume>166</volume>
        <year>2016</year>
        <fpage>755</fpage>
        <lpage>765</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2016.05.069</pub-id>
        <pub-id pub-id-type="pmid">27372738</pub-id>
      </element-citation>
    </ref>
    <ref id="bib47">
      <element-citation publication-type="journal" id="sref47">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Liu</surname>
            <given-names>T.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Z.</given-names>
          </name>
          <name>
            <surname>Payne</surname>
            <given-names>S.H.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B.</given-names>
          </name>
          <name>
            <surname>McDermott</surname>
            <given-names>J.E.</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>J.Y.</given-names>
          </name>
          <name>
            <surname>Petyuk</surname>
            <given-names>V.A.</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Ray</surname>
            <given-names>D.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated proteogenomic characterization of human high-grade serous ovarian cancer</article-title>
        <source>Cell</source>
        <volume>166</volume>
        <year>2016</year>
        <fpage>755</fpage>
        <lpage>765</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2016.05.069</pub-id>
        <pub-id pub-id-type="pmid">27372738</pub-id>
      </element-citation>
    </ref>
    <ref id="bib48">
      <element-citation publication-type="journal" id="sref48">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>J.</given-names>
          </name>
          <name>
            <surname>Bajari</surname>
            <given-names>R.</given-names>
          </name>
          <name>
            <surname>Andric</surname>
            <given-names>D.</given-names>
          </name>
          <name>
            <surname>Gerthoffert</surname>
            <given-names>F.</given-names>
          </name>
          <name>
            <surname>Lepsa</surname>
            <given-names>A.</given-names>
          </name>
          <name>
            <surname>Nahal-Bose</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Stein</surname>
            <given-names>L.D.</given-names>
          </name>
          <name>
            <surname>Ferretti</surname>
            <given-names>V.</given-names>
          </name>
        </person-group>
        <article-title>The international cancer genome Consortium data portal</article-title>
        <source>Nat. Biotechnol.</source>
        <volume>37</volume>
        <year>2019</year>
        <fpage>367</fpage>
        <lpage>369</lpage>
        <pub-id pub-id-type="doi">10.1038/s41587-019-0055-9</pub-id>
        <pub-id pub-id-type="pmid">30877282</pub-id>
      </element-citation>
    </ref>
    <ref id="bib49">
      <element-citation publication-type="journal" id="sref49">
        <person-group person-group-type="author">
          <name>
            <surname>Zou</surname>
            <given-names>K.</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>M.</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>H.</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>L.</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>Y.</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>S.</given-names>
          </name>
          <name>
            <surname>Dai</surname>
            <given-names>X.</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>W.</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Potential role of HMGCS2 in tumor angiogenesis in colorectal cancer and its potential use as a diagnostic marker</article-title>
        <source>Can. J. Gastroenterol. Hepatol.</source>
        <volume>2019</volume>
        <year>2019</year>
        <fpage>8348967</fpage>
        <pub-id pub-id-type="doi">10.1155/2019/8348967</pub-id>
        <pub-id pub-id-type="pmid">31355161</pub-id>
      </element-citation>
    </ref>
  </ref-list>
  <sec id="appsec2" sec-type="supplementary-material">
    <title>Supplemental information</title>
    <p id="p0220">
      <supplementary-material content-type="local-data" id="mmc1">
        <caption>
          <title>Document S1. Figure S1 and Tables S1–S3</title>
        </caption>
        <media xlink:href="mmc1.pdf"/>
      </supplementary-material>
    </p>
  </sec>
  <ack id="ack0010">
    <title>Acknowledgments</title>
    <p id="p0200">The authors acknowledge the developers of the original annotation resources to share their data. This work was supported by <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/100017950</institution-id><institution>Shanghai Municipal Health Commission</institution></institution-wrap></funding-source> and <funding-source id="gs2">Collaborative Innovation Cluster Project</funding-source> (No. 2019CXJQ02). It was also supported by <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001809</institution-id><institution>National Natural Science Foundation of China</institution></institution-wrap></funding-source> grants (Nos. 31878209, 31671377), <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100003399</institution-id><institution>Shanghai Municipal Science and Technology Commission of China</institution></institution-wrap></funding-source> (No. 17ZR1420300), <funding-source id="gs5">Shanghai Municipal Science and Technology Major Project</funding-source> (Grant No. 2017SHZDZX01, 20692191500), <funding-source id="gs6">Beihang University &amp; Capital Medical University Plan</funding-source> (BHME-201904) and the <funding-source id="gs7">Open Research Fund of Key Laboratory of Advanced Theory</funding-source> and Application in Statistics and Data Science-<funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002338</institution-id><institution>MOE</institution></institution-wrap></funding-source>, <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004106</institution-id><institution>ECNU</institution></institution-wrap></funding-source>.</p>
    <sec id="sec6">
      <title>Author contributions</title>
      <p id="p0205">L.X., T.S., and G.Q. designed the study, J.O. constructed the database and developed the webservice, J.O. and G.Q. developed the analyses pipelines. J.O. and Z.L. did the data preprocessing. X.J. and Z.L. tested the website. J.O., G.Q., L.X., and T.S. wrote the manuscript. All authors read and approved the final manuscript.</p>
    </sec>
    <sec sec-type="COI-statement" id="sec7">
      <title>Declaration of interests</title>
      <p id="p0210">The authors declare no competing interests.</p>
    </sec>
  </ack>
  <fn-group>
    <fn id="appsec1" fn-type="supplementary-material">
      <p id="p0215">Supplemental information can be found online at <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.isci.2022.104190" id="intref0125">https://doi.org/10.1016/j.isci.2022.104190</ext-link>.</p>
    </fn>
  </fn-group>
</back>
